96 related articles for article (PubMed ID: 8650021)
1. [Activity of plasminogen activator inhibitor (PAI-1) in plasma of women treated after menopause with hormone replacement therapy].
Ciepłuch R; Czestochowska E
Pol Tyg Lek; 1995 Sep; 50(36-39):13-5. PubMed ID: 8650021
[TBL] [Abstract][Full Text] [Related]
2. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women.
Koh KK; Mincemoyer R; Bui MN; Csako G; Pucino F; Guetta V; Waclawiw M; Cannon RO
N Engl J Med; 1997 Mar; 336(10):683-90. PubMed ID: 9041098
[TBL] [Abstract][Full Text] [Related]
3. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
[TBL] [Abstract][Full Text] [Related]
4. Hormone replacement therapy and hemostasis: effects in Brazilian postmenopausal women.
Callejon DR; Franceschini SA; Montes MB; Toloi MR
Maturitas; 2005; 52(3-4):249-55. PubMed ID: 16257613
[TBL] [Abstract][Full Text] [Related]
5. Effect of the cessation of long-term hormone replacement therapy on plasma plasminogen activator inhibitor-1 and fibrinogen.
Kalela A; Jokela H; Lehtimäki T; Uppa H; Kunnas T; Teisala K; Punnonen R; Nikkari ST
Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):217-20. PubMed ID: 16337074
[TBL] [Abstract][Full Text] [Related]
6. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
[TBL] [Abstract][Full Text] [Related]
7. Changes in hemostatic variables induced by estrogen replacement therapy: comparison of transdermal and oral administration in a crossover-designed study.
Fait T; Vrablik M; Zizka Z; Kostirova M
Gynecol Obstet Invest; 2008; 65(1):47-51. PubMed ID: 17713346
[TBL] [Abstract][Full Text] [Related]
8. Effect of estrogen therapy on insulin resistance and plasminogen activator inhibitor type 1 concentrations in postmenopausal women.
Saucedo R; Basurto L; Zarate A; Martínez C; Hernandez M; Galván R
Gynecol Obstet Invest; 2007; 64(2):61-4. PubMed ID: 17264514
[TBL] [Abstract][Full Text] [Related]
9. Short-term results of transdermal estrogen replacement therapy in cardiovascular disease-free postmenopausal females with and without hypertension.
Modena MG; Rossi R; Muia N; Origliani G; Rombolà O; Molinari R
G Ital Cardiol; 1998 Jun; 28(6):636-44. PubMed ID: 9672776
[TBL] [Abstract][Full Text] [Related]
10. [Changes of plasminogen activator inhibitor (PAI-1) during estrogen replacement therapy].
Zizka Z; Fait T; Vrablík M
Cas Lek Cesk; 2007; 146(11):874-7. PubMed ID: 18069215
[TBL] [Abstract][Full Text] [Related]
11. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.
Grancha S; Estellés A; Tormo G; Falco C; Gilabert J; España F; Cano A; Segui R; Aznar J
Thromb Haemost; 1999 Apr; 81(4):516-21. PubMed ID: 10235431
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
[TBL] [Abstract][Full Text] [Related]
14. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. The Writing Group for the Estradiol Clotting Factors Study.
Thromb Haemost; 1996 Mar; 75(3):476-80. PubMed ID: 8701411
[TBL] [Abstract][Full Text] [Related]
15. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women.
Ichikawa J; Sumino H; Ichikawa S; Ozaki M
Am J Hypertens; 2006 Jul; 19(7):744-9. PubMed ID: 16814131
[TBL] [Abstract][Full Text] [Related]
16. Effects of long-term transdermal hormone replacement therapy on the renin-angiotensin- aldosterone system, plasma bradykinin levels and blood pressure in normotensive postmenopausal women.
Ichikawa A; Sumino H; Ogawa T; Ichikawa S; Nitta K
Geriatr Gerontol Int; 2008 Dec; 8(4):259-64. PubMed ID: 19149837
[TBL] [Abstract][Full Text] [Related]
17. Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women.
Bonduki CE; Lourenço DM; Baracat E; Haidar M; Noguti MA; da Motta EL; Lima GR
Acta Obstet Gynecol Scand; 1998 Mar; 77(3):330-3. PubMed ID: 9539282
[TBL] [Abstract][Full Text] [Related]
18. Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease.
Lindoff C; Peterson F; Lecander I; Martinsson G; Astedt B
Maturitas; 1996 May; 24(1-2):43-50. PubMed ID: 8794433
[TBL] [Abstract][Full Text] [Related]
19. Effects of progestogen on lipids, lipoproteins and apolipoproteins during transdermal estrogen replacement therapy with and without medroxyprogesterone acetate.
Castelo-Branco C; Casals E; Sanllehy C; Duran M; Fortuny A; Vanrell JA
J Reprod Med; 1996 Nov; 41(11):833-8. PubMed ID: 8951134
[TBL] [Abstract][Full Text] [Related]
20. [Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol].
Milewicz T; Kostecka A; Rogatko I; Sztefko K; Kwiatkowska-Panek E; Radowick S; Krzysiek J
Przegl Lek; 2007; 64(2):65-9. PubMed ID: 17892034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
